Peptides for perimenopause and menopause: do any really help?
Hormone therapy and 3 nonhormone pills are the FDA-approved hot flash options. None of them is a peptide.
By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Not yet reviewed by a licensed clinician. How we check facts

Are peptides good for menopause?
- It depends on what you want help with. No peptide is FDA approved for menopause itself.
- A few approved peptide drugs treat problems that are common after 40, like extra weight or thin bones.
- We found no menopause studies in people for peptides sold online, like BPC-157, CJC-1295 or ipamorelin. That means nobody knows if they help or harm.
- FDA status, proof that it works, and safety are 3 different questions. We rate each one on its own below.
Do peptides help with perimenopause?
- Perimenopause is the time before menopause when hormone levels change. It usually starts in your mid- to late 40s and lasts about 4 years on average, but it can last up to 10 years, says womenshealth.gov.
- No peptide is FDA approved for perimenopause symptoms. We found no perimenopause trials in people for peptides sold online, like BPC-157 or CJC-1295.
- Your doctor can usually tell if you are in perimenopause from your age, symptoms and periods. Blood hormone tests are not usually needed, says womenshealth.gov.
- You can still get pregnant in perimenopause. That matters for GLP-1 drugs: the Wegovy label says to stop it at least 2 months before a planned pregnancy, and the Zepbound label says it can make birth control pills work less well for 4 weeks after you start and after each dose increase.
Do peptides help with hot flashes?
- No peptide is FDA approved for hot flashes or night sweats.
- The FDA has approved hormone therapy for moderate to severe hot flashes, says the Office on Women’s Health (womenshealth.gov).
- The FDA has also approved 3 nonhormone medicines for moderate to severe hot flashes: a low-dose paroxetine (Brisdelle), fezolinetant (Veozah) and elinzanetant (Lynkuet). None of these is a peptide.
- Each one has its own risks. The Veozah label has a boxed warning about liver injury and asks for liver blood tests. The Brisdelle label has a boxed warning about suicidal thoughts, like other SSRIs.
- Talk therapy (CBT) and clinical hypnosis may also help hot flashes bother you less, says womenshealth.gov.
What peptides help with menopause weight gain and belly fat?
- Wegovy (semaglutide) and Zepbound (tirzepatide) are peptide drugs. The FDA approved them for adults with obesity, or with overweight and a weight-related health problem. They are not approved for menopause itself.
- In the STEP 1 trial, adults on the semaglutide shot lost about 14.9% of their weight in 68 weeks, vs 2.4% on placebo. That trial was not only for women in menopause.
- Tesamorelin (Egrifta SV) lowers deep belly fat, but it is approved only for adults with HIV who have that problem.
- No peptide is approved for "menopause belly fat."
Can peptides help bones after menopause?
- Yes, 2 peptide drugs are FDA approved for this. Forteo (teriparatide) and Tymlos (abaloparatide) treat osteoporosis (thin, weak bones) in women after menopause who have a high chance of breaking a bone.
- In a big trial, new spine fractures happened in about 14 of 100 women on placebo, vs about 5 of 100 on teriparatide.
- In another big trial, women on abaloparatide had fewer new spine fractures than women on placebo.
- The Forteo label says its most common side effects are joint pain, pain and nausea. The Tymlos label lists extra calcium in the urine, dizziness, nausea, headache, a pounding heartbeat, tiredness, upper belly pain and a spinning feeling.
- These are shots that a doctor must prescribe.
Do peptides help low sex drive in menopause?
- Vyleesi (bremelanotide, also called PT-141) is an FDA-approved peptide for low sexual desire that causes distress. But it is approved only for women who have not gone through menopause yet.
- The Vyleesi label says it is not for women after menopause and not for men.
- Its trials tested women before menopause. The average age was 39.
Are peptides safe for women over 40 and 50?
- Approved peptide drugs have known risks on their FDA labels. Your doctor can check them against your health.
- Most peptides sold online have very little safety data. No data does not mean safe. It also does not prove they fail. It means the risks are unknown.
- The FDA has put some peptides on a list of bulk drug ingredients that may have serious safety risks.
- "Not FDA approved" is not always the same as illegal. It depends on what the product is and how it is sold. See our legal guide.
Did the FDA change the hormone therapy warnings?
- Yes. In November 2025, the FDA started removing boxed warnings about heart disease, breast cancer and dementia from menopause hormone therapy labels.
- On February 12, 2026, the FDA approved the first 6 updated labels. The boxed warning about cancer of the uterus lining stays for estrogen-only pills and patches taken for the whole body.
- Hormone therapy is not a peptide. It still has risks, like blood clots and stroke, says womenshealth.gov. Ask your doctor what fits you.
Do collagen peptides or skin peptide creams help after menopause?
- Collagen peptide powders are sold as supplements. The FDA does not approve supplements before they are sold.
- Skin creams are cosmetics. The FDA says cosmetics (except color additives) do not need FDA approval before sale.
- The FDA says a cream that claims to regrow hair or "regenerate cells" is treated as a drug, not just a cosmetic.
- We found no FDA-approved peptide cream or powder for menopause.
The numbers in charts
Weight loss in big obesity drug trials
% of starting body weight lost, drug vs placebo (fake shot)
Tirzepatide 15 mg (Zepbound)SURMOUNT-1 · 2,539 adults · 72 weeks
Semaglutide 2.4 mg (Wegovy)STEP 1 · 1,961 adults · 68 weeks
Liraglutide 3.0 mg (Saxenda)SCALE · 3,731 adults · 56 weeks
Different trials, different people: not a head-to-head comparison.
Show the numbers as a table
| Trial | Drug | Placebo |
|---|---|---|
| Tirzepatide 15 mg (Zepbound) SURMOUNT-1 · 2,539 adults · 72 weeks | −20.9% | −3.1% |
| Semaglutide 2.4 mg (Wegovy) STEP 1 · 1,961 adults · 68 weeks | −14.9% | −2.4% |
| Liraglutide 3.0 mg (Saxenda) SCALE · 3,731 adults · 56 weeks | −7.4% | −3.0% |
New spine fractures on bone-building shots
% of women with weak bones who got a new spine fracture, drug vs placebo
Teriparatide 20 µg (Forteo)1,637 women · about 21 months
Abaloparatide (Tymlos)ACTIVE · 1,401 women in this count · 18 months
Different trials, different people: not a head-to-head comparison. Lower is better.
Show the numbers as a table
| Trial | Drug | Placebo |
|---|---|---|
| Teriparatide 20 µg (Forteo) 1,637 women · about 21 months | 5% | 14% |
| Abaloparatide (Tymlos) ACTIVE · 1,401 women in this count · 18 months | 0.6% | 4.2% |
Studies in people
| Study type | People | Main finding | Limits |
|---|---|---|---|
| Randomized trial: teriparatide (Forteo) vs placebo, 2001 | 1,637 women after menopause who had broken a spine bone | New spine fractures: about 14% on placebo vs 5% on teriparatide | Women already had fractures; about 21 months |
| Randomized trial: abaloparatide (Tymlos) vs placebo (ACTIVE), 2016 | 2,463 women after menopause with osteoporosis | Fewer new spine and other fractures than placebo | 18 months; the teriparatide group was not blinded |
| Randomized trial: semaglutide shot vs placebo (STEP 1), 2021 | 1,961 adults with obesity or overweight | Weight went down 14.9% vs 2.4% in 68 weeks | Not a menopause study |
| 2 randomized trials: bremelanotide (Vyleesi) vs placebo (RECONNECT), 2019 | 1,267 women before menopause (1,247 got at least one dose), average age 39 | More sexual desire and less distress than placebo | Not tested after menopause |
| Review of all human studies: BPC-157, 2026 | 3 small studies, 30 people in total | Most people said they felt better | Poor-quality studies; none about menopause |
Menopause options: FDA status, proof and safety
| FDA status | Proof it works in people | Safety data | |
|---|---|---|---|
| Hormone therapy (not a peptide) | Approved for hot flashes, bone loss and vaginal dryness | Strong for those uses | Well studied; labels list risks |
| Brisdelle, Veozah, Lynkuet (not peptides) | Approved for moderate to severe hot flashes | Enough for FDA approval | Labels list risks; Veozah has a liver warning |
| Wegovy, Zepbound (peptides) | Approved for weight in adults with obesity, not for menopause itself | Strong for weight loss | Well studied |
| Forteo, Tymlos (peptides) | Approved for weak bones after menopause | Strong: fewer spine fractures | Well studied |
| Vyleesi / PT-141 (peptide) | Approved only before menopause, for low desire | Some, before menopause only | Studied before menopause only |
| BPC-157, CJC-1295, ipamorelin (peptides) | Not FDA approved | No menopause studies in people | Very little |
FAQ
Can GLP-1s help with perimenopause weight gain?
Wegovy and Zepbound are approved for adults with obesity, or with overweight and a weight-related health problem, at any adult age. They are not approved for perimenopause itself, and we found no big trial done only in women in perimenopause. Ask your doctor if you qualify.
Is GLP-1 microdosing good for perimenopause?
We found no published study of GLP-1 "microdosing" in perimenopause (PubMed search, Nov 2, 2026). Using doses outside the FDA label is something to decide only with your doctor.
Can a peptide replace estrogen?
No. No peptide is approved to replace estrogen or progesterone. Ask your doctor which approved choice fits your symptoms and health history.
Is testosterone approved for women in menopause?
No. Womenshealth.gov says the FDA has not approved testosterone for women. Some doctors still talk about it with patients, so ask about the risks.
Is kisspeptin used for menopause?
Kisspeptin-10 is not FDA approved for any use. It is still on the FDA list of risky bulk ingredients for regular pharmacies.
Does PT-141 work after menopause?
It was not tested after menopause in its main trials, and its FDA label says it is not for that group. So nobody knows.
Who can I call with menopause questions?
The Office on Women’s Health helpline is 1-800-994-9662, weekdays 9 a.m. to 6 p.m. Eastern. It shares information but does not give medical advice.
Are Forteo and Tymlos for everyone with low bone density?
No. They are approved for women after menopause with osteoporosis who have a high chance of breaking a bone, or when other bone drugs did not work or were not tolerated.
Related pages
- Forteo (teriparatide)FDA approved · Proof: Strong
- Tymlos (abaloparatide)FDA approved · Proof: Strong
- GLP-1: Wegovy / Ozempic (semaglutide)FDA approved · Proof: Strong
- GLP-1: Zepbound / Mounjaro (tirzepatide)FDA approved · Proof: Strong
- Vyleesi (bremelanotide, PT-141)FDA approved · Proof: Some
- BPC-157Not approved · Proof: Early
- CJC-1295Not approved · Proof: Early
- Kisspeptin-10Not approved · Proof: Early
- Peptides for libido and sex drive: what works?Guide
- Peptides for sleep, anxiety and brain fog: do any work?Guide
- Peptides for osteoporosis and bone density: what works?Guide
- Can peptides make you infertile?Guide
- Do peptides really work? The honest answerGuide
- Peptides vs TRT vs SARMs: which is safer?Guide
- Are Peptides Safe? What to Know FirstGuide
- Can a doctor prescribe peptides?Guide
- Peptide side effects checkerTool
- Questions to ask your doctorTool
- Is there a peptide for my goal?Tool
- Compare Forteo vs TymlosComparison tool
We never share doses or tell you where to buy. Always ask your doctor. Print our doctor questions sheet.
Sources
- Office on Women's Health (womenshealth.gov): Menopause basics and perimenopause (updated Oct 19, 2026)
- Office on Women's Health (womenshealth.gov): Menopause treatment (updated Oct 19, 2026)
- FDA: FDA approves labeling changes to menopausal hormone therapy products (Feb 12, 2026)
- FDA: HHS removes misleading FDA warnings on hormone replacement therapy (Nov 10, 2025)
- DailyMed (FDA label): Brisdelle (paroxetine) prescribing information
- DailyMed (FDA label): Veozah (fezolinetant) prescribing information
- DailyMed (FDA label): Lynkuet (elinzanetant) prescribing information
- DailyMed (FDA label): Wegovy (semaglutide) injection and tablets prescribing information, revised 6/2026
- DailyMed (FDA label): Zepbound (tirzepatide) prescribing information
- DailyMed (FDA label): Egrifta SV (tesamorelin) prescribing information
- DailyMed (FDA label): Forteo (teriparatide) prescribing information
- DailyMed (FDA label): Tymlos (abaloparatide) prescribing information
- DailyMed (FDA label): Vyleesi (bremelanotide) prescribing information
- PubMed: Neer et al., Parathyroid hormone (1-34) on fractures in postmenopausal women with osteoporosis, NEJM 2001
- PubMed: Miller et al., Abaloparatide vs placebo on new vertebral fractures (ACTIVE), JAMA 2016
- PubMed: Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021
- PubMed: Kingsberg et al., Bremelanotide for hypoactive sexual desire disorder: two phase 3 trials (RECONNECT), Obstet Gynecol 2019
- PubMed: Poolton et al., Human evidence for BPC-157: a systematic review, Acta Orthop Belg 2026
- FDA: Bulk drug substances that may present significant safety risks (Category 2 and withdrawn list)
- FDA: Questions and answers on dietary supplements (FDA does not approve supplements before sale)
- FDA: Is it a cosmetic, a drug, or both?